From diagnosis to treatments and trials Every route, cited.
MedaRoute shows what the EMA and the FDA approved, refused or designated for a rare disease, and the clinical trials. Every statement links to the agency’s own text.
MedaRoute shows what the EMA and the FDA approved, refused or designated for a rare disease, and the clinical trials. Every statement links to the agency’s own text.
How it works
MedaRoute reads the public records of the European Medicines Agency, the US Food and Drug Administration and the clinical-trial registries, and puts them on one page per disease.
Type the disease you are looking into, in English or as an abbreviation.
What the EMA and the FDA approved, refused or designated, from their own decisions, and the trials registered for the disease.
Each line links to the passage in the agency’s document it comes from, so you can check it at the source.
What to expect
MedaRoute is for doctors, for patients and their families, and for the companies that develop treatments. It starts with a small set of rare diseases and grows from there.